Skip to content

Main Navigation

About us
Innovation and research
Pipeline
Partnering
- - - Our approach
    - Our partnerships
Investors
Media
Careers
ESG

test

Search

Recent Posts

Nykode Therapeutics Initiates Phase 1/2a Trial of VB10.16 in First Line HPV16-Positive Head and Neck Cancer
Nykode Therapeutics – presentation from Capital Markets Day in Oslo
Nykode Therapeutics – Capital Markets Day in Oslo on September 27, 2023 – presentation
Nykode Therapeutics – Capital Markets Day in Oslo on September 27, 2023
Nykode Therapeutics – Capital Markets Day in New York on September 20, 2023

Recent Comments

Vaccibody Granted Platform Patent in the US (16.02.15) | Sarsiaseed on Vaccibody Granted Platform Patent in the US
Vaccibody får viktig patent godkjent i USA (16.02.15) | Sarsiaseed on Vaccibody Granted Platform Patent in the US

Contact

Headquarter, Norway
Nykode Therapeutics ASA
Oslo Science Park, Gaustadalléen 21
0349 Oslo
Norway
Phone +47 22 95 81 93

Office, Denmark
Gammel Lundtoftevej 1E, 3. Sal.
2800 Lyngby
Denmark

Privacy statement
Cookie policy
Disclaimer